Rosen, Querfeld awarded $7.5M to develop better treatment for CTCL

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

City of Hope has received $7.5 million in grant awards to study cutaneous T cell lymphoma.

NCI awarded two grants valued at $6.3 million over five years to City of Hope’s Steven Rosen and Christiane Querfeld to work on developing improved therapies for CTCL, a disfiguring, incurable cancer that affects about 3,000 new individuals each year.

The Leukemia & Lymphoma Society also gave the researchers two individual grants totaling $1.2 million over three years. Rosen and Querfeld will approach the problem from different angles in their respective laboratories.

“City of Hope is creating a national model for how to treat CTCL,” Rosen, its provost, chief scientific officer and the Morgan & Helen Chu Director’s Chair of the Beckman Research Institute, said in a statement. “Symptoms can include large, disfiguring plaques and tumors on the skin or a red rash that may cover the entire body. You can’t imagine the joy in patients’ eyes when our experimental treatments mollify CTCL symptoms. We are grateful for the trust the federal government and The Leukemia & Lymphoma Society have in us and our results.”

Querfeld, chief of dermatology and director of City of Hope’s Cutaneous Lymphoma Program and a Schwartz Ward Family Foundation LLS Scholar, has been studying and treating patients with CTCL for 17 years.

She will use her grants to advance her clinical phase I/II trial that looked at immune checkpoint PD1/PD-L1 inhibition. Her team will map the communication network among the disease’s cellular, molecular and immunological microenvironment. Blocking or silencing certain communication networks could eliminate tumors or cancers, she said.

“The result of this newly funded study will allow physicians to use personalized medicine for certain patients with CTCL,” Querfeld said in a statement. “We will identify potential therapeutic targets and correlative markers that help guide immunotherapy treatments.”

Querfeld was mentored by Rosen, City of Hope’s Irell & Manella Cancer Center Director’s Distinguished Chair, when she first entered the research world. CTCL has been one of Rosen’s research foci since the 1980s. He has identified novel groups of targets to advance the development of therapeutic compounds for this disease.

His NCI and LLS grant awards will build the foundational knowledge scientists need to develop targeted drug therapies for people with CTCL. Specifically, he will look at molecular regulators like p38γ, a protein kinase that is overexpressed in CTCL cells, but not in healthy immune T cells.

Conventional treatments for CTCL work for a few months, and only about 30% of patients respond to treatment, Querfeld said.

Table of Contents

YOU MAY BE INTERESTED IN

U.S. Deputy Secretary for Health and Human Services, Andrea Palm, and Sweden's Minister for Health Care, Acko Ankarberg Johansson, signing the agreement. Credit: Joel Apelthun/Government Offices of SwedenThe United States and Sweden signed an agreement to step up collaborations in science and technology by focusing on cancer research.

Login